Sumanta K. Pal, MD, FASCO, on CONTACT-03 Trial and Investigating Targeted Therapy, Immunotherapy for Patients with RCC

Video

Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® about the plan for the CONTACT-03 study (NCT04338269), which is examining cabozantinib (Cabometyx) either alone or in combination with atezolizumab (Tecentriq) in renal cell carcinoma following progression on immune checkpoint inhibitors, and what the research team hopes to see with the data, from an abstract presented at the 2021 Genitourinary Cancers Symposium.

Transcription:

What I would suggest is that, at this point in time, the current clinical practice is that patients receive checkpoint inhibitors in the upfront setting in combination with targeted therapy. And then after that, targeted therapy should be the standard. But we actually see a lot of patients still receiving targeted therapy with immunotherapy. And right now, there’s really no basis for that. What we’re hoping to do with the CONTACT-03 study is either add some credibility to that approach, or to demonstrate that there is no benefit with a re-challenge with immunotherapy. I think that data is really vital because without it, there’s really no substantiation for using checkpoint inhibitors beyond initial progression, and there’s the chance that we could be hurting patients with added toxicity, but no additional benefit.

Reference:

Pal SK, Albiges L, Rodriguez CS, et al. CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma. Presented at: 2021 Genitourinary Cancers Symposium. Abstract TPS370.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Related Content